Adipose tissue located inside the abdominal cavity, including visceral fat and retroperitoneal fat.
1Some, but not all, studies demonstrate reductions in visceral adipose tissue.
2EPC were found in both subcutaneous and visceral adipose tissue specimens.
3Background: Increased abdominal visceral adipose tissue (VAT) is associated with systemic inflammation.
4These values were higher in the subcutaneous adipose tissue compared with visceral adipose tissue.
5However, treatment with both Uro-A and Uro-B decreased body weight and visceral adipose tissue mass.
6Individuals with high visceral adipose tissue levels have higher blood pressure, independent of their fitness.
7Impaired muscle strength and a high amount of visceral adipose tissue are associated with worse survival.
8Multispectral immunofluorescence imaging and immunoblot were applied to characterize sympathetic neurons and macrophages in visceral adipose tissue.
9This risk has been attributed to visceral adipose tissue (vAT) expansion associated with increased proinflammatory mediators.
10We examined how these beverages associate with regional abdominal adiposity measures, specifically visceral adipose tissue (VAT).
11Associations of visceral adipose tissue and abdominal subcutaneous adipose tissue were associated with both histologic and MRS-measured steatosis.
12The reduced TRPV1 expression in visceral adipose tissue from obese humans was accompanied by reduced capsaicin-induced calcium influx.
13Telmisartan treatment decreased the weight of visceral adipose tissue and the triglyceride content in the liver and skeletal muscle.
14A whole genome expression profile of four tissues was available: liver, muscle, subcutaneous adipose tissue and visceral adipose tissue.
15Results: Indeed, a high-fat diet resulted in increased body weight, visceral adipose tissue mass, and oxidative stress in rats.
16We detected TRPV1 channels in 3T3-L1-preadipocytes and visceral adipose tissue from mice and humans.
Translations for visceral adipose tissue